BioPharma Dive October 24, 2024
The latest biotech arrival on Nasdaq entered the clinic last month with its lead drug candidate, a treatment for hypoparathyroidism.
Septerna, a developer of medicines that target a ubiquitous family of proteins, on Thursday priced a $288 million initial public offering that again showed investors’ support of biotechnology companies that have reached clinical testing.
The company sold 16 million shares at $18 apiece, slightly above the $15 to $17 range it had set in a securities filing Monday. It also sold substantially more shares than originally expected, having boosted its offering’s size hours before pricing. Shares of “SEPN” will begin trading Friday on the Nasdaq stock exchange.
Prior to joining Nasdaq, the California company raised more than $200 million in...
Today's Sponsors
Today's Sponsor